Clinical trials: GVHD, Acute
Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD
MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients
MaaT013 showed interesting results in steroids and ruxolitinib-resistant aGVHD patients with gut involvement (55% ORR at D28) and 47% and 39% OS at 6 and 12 months respectively (Malard 2020), therefore warrant being tested as…
- Trial name
- ARES (NCT04769895)
- Testing
- MaaT013
- Where
- 50 sites in Austria, Belgium and 4 more
- Volunteers
- 66 people
- Sponsor
- MaaT Pharma
Acute GVHD
Ruxolitinib and Steroid As First Line Therapy for Acute GVHD
The purpose of this study is to evaluate the efficacy of ruxolitinib in combination with methylprednisolone as first line therapy in patients with Grades II to IV acute graft-versus-host disease (GVHD).
- Trial name
- NCT03701698
- Testing
- Ruxolitinib Oral Tablet, Methylprednisolone
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Acute Graft Versus Host Disease in Intestine, Steroid Refractory GVHD
Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease
MaaT013 is still in clinical development phase and is not approved yet for marketing in any region. During the development program, MaaT Pharma has undertaken initial development with closely related product candidates, leading…
- Trial name
- ATLAS (NCT04768907)
- Testing
- MaaT013
- Where
- 46 sites in Austria, Belgium and 6 more
- Sponsor
- MaaT Pharma
Acute Graft-Versus-Host Disease (Gvhd) Grade, Hematopoietic Cell Transplantation
FMT In High-Risk Acute GVHD After ALLO HCT
The purpose of this study is to evaluate the effectiveness of Fecal Microbiota Transplant (FMT) treatment in high-risk acute graft-versus-host disease (GVHD). This research study involves an experimental intervention called FMT.
- Conditions
- Acute Graft-Versus-Host Disease (Gvhd) Grade, Hematopoietic Cell Transplantation, Fecal Microbiota Transplant
- Trial name
- NCT04139577
- Testing
- Fecal Microbiota Transplant
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Acute GVHD
Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)
The purpose of this research study is to evaluate tacrolimus plasma concentrations in patients who will undergo an allogeneic hematopoietic stem cell transplant (HCT).
- Trial name
- NCT04645667
- Testing
- Tacrolimus
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
GVHD, Acute Stem Cell Transplant Complications
MAP-guided Preemptive Therapy of aGvHD by Ruxolitinib
The goal of this observation study is to test in patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT).
- Trial name
- NCT06075225
- Testing
- Ruxolitinib
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sichuan University
Allogeneic Disease, GVHD,Acute
Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis
Despite progress in chemotherapy, targeted therapy and immunotherapy, allogeneic hematopoietic stem cell transplantation (allo-SCT) is still the only curative procedure for some hematological malignancies.
- Conditions
- Allogeneic Disease, GVHD,Acute, Graft Failure
- Trial name
- HAPLO-GEL (NCT05855707)
- Testing
- WJ-MSC infusion
- Volunteers
- 12 people
- Sponsor
- Central Hospital, Nancy, France
Low Risk Acute Graft-versus-host Disease, Graft-versus-host-disease
Itacitinib for Low Risk GVHD
Graft-versus-host disease (GVHD) is treated with high doses of systemic steroids which can lead to serious complications. A new blood test can identify patients whose GVHD is most likely to respond to well to treatment (low risk…
- Conditions
- Low Risk Acute Graft-versus-host Disease, Graft-versus-host-disease, GVHD
- Trial name
- NCT03846479
- Testing
- Itacitinib
- Where
- 14 sites in United States
- Volunteers
- 70 people
- Sponsor
- John Levine
GVHD,Acute
Mesenchymal Stem Cells (MSCs) for Steroid Refractory Acute GVHD (SR-aGVHD)
The objective of this clinical study is to demonstrate safety and feasibility of single-dose infusion of Ossium MSCs product (OSSM-001) to treat steroid refractory acute GVHD (SR-aGVHD).
- Trial name
- NCT05443464
- Testing
- OSSM-001
- Sponsor
- Ossium Health, Inc.
Relapsed Pediatric ALL, Acute Graft-Versus-Host Disease (Gvhd) Grade IV (Diagnosis)
TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia
This is a multi-center clinical study in China using CliniMACS TCRα/β+ and CD45RA+ T cell depleted stem cell grafts from haploidentical donors for hematopoietic stem cell transplantation in children.
- Conditions
- Relapsed Pediatric ALL, Acute Graft-Versus-Host Disease (Gvhd) Grade IV (Diagnosis), Relapsed Pediatric AML
- Trial name
- NCT04033627
- Testing
- In Vitro T cells depletion using CliniMCAS system
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Children's Medical Center
GVHD,Acute, GVHD, Chronic
Physiotherapy and Therapeutic Exercise Program in Graft-versus-host Disease (GvHD)
Range of motion, antropometric measurements, quality of life questionnaire and 2 minutes walk test will be implemented as an initial assessment.
- Trial name
- NCT05401955
- Testing
- Physical exercise
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- University of Salamanca
GVHD,Acute, Stem Cell Transplant Complications
MAP-guided Preemptive Therapy of aGvHD
Acute graft versus host disease (aGvHD) is a severe and potentially fatal complication of allogeneic hematopoietic stem cell transplantation (HCT).
- Trial name
- NCT05368181
- Testing
- Methylprednisolone
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Sichuan University
Acute GVHD
A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)
The study is a Phase II randomized, open label, multicenter trial designed to identify whether sirolimus is a potential alternative to prednisone as an up-front treatment for patients with standard-risk acute GVHD defined…
- Trial name
- NCT02806947
- Testing
- Sirolimus, Prednisone
- Where
- 21 sites in United States
- Volunteers
- 127 people
- Sponsor
- Medical College of Wisconsin
Leukemia, Lymphoma, Non-Hodgkin
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
GVHD prophylaxis of sirolimus and mycophenolate mofetil for patients undergoing matched related allogeneic transplant for acute and chronic leukemia, MDS, high risk NHL and HL
- Conditions
- Leukemia, Lymphoma, Non-Hodgkin, Hematologic Diseases, Acute GVHD
- Trial name
- NCT00350181
- Testing
- Sirolimus, MMF, BCNU
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Stanford University
GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)
Phase I Study of Milatuzumab for Graft Versus Host Disease
This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.
- Conditions
- GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT01663766
- Testing
- milatuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gilead Sciences
GVHD, Acute
PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT
All patients received Flu-BU-VP16 as myeloablative conditioning followed by cyclophosphamide (D+3 and +4) and subsequent tacrolimus. For patients with unrelated or haplo-donor received low-dose ATG at Day +15.
- Trial name
- NCT04118075
- Testing
- PT-CY-FK +/-ATG
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
GVHD, Chronic, Acute Leukemia
Electronic Database for the Follow up of the ATG_FamilyStudy
Allogeneic hematopoietic stem cell transplantation (HSCT) is capable of definitive cure of acute leukemias. The most important post-transplant complication is graft vs host disease (GVHD) which can be substantially decreased by…
- Conditions
- GVHD, Chronic, Acute Leukemia, Stem Cell Transplant Complications
- Trial name
- AFF (NCT03042676)
- Where
- Italy
- Volunteers
- 104 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Acute GvHD
Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)
The purpose of this study is to determine the safe and tolerable, biologically active, and potentially effective doses(s) of ALD518 in subjects with acute GVHD, who have failed to respond to glucocorticosteroids, for further…
- Trial name
- ALD518-010 (NCT01530256)
- Testing
- ALD518
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- CSL Behring
GVHD,Acute
A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease
The purpose of this study is to evaluate itacitinib in combination with corticosteroids as first-line treatment of participants with Grade II to IV acute graft-versus-host disease (aGVHD).
- Trial name
- NCT04220632
- Testing
- Itacitinib, Prednisone, Methylprednisolone
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
GVHD, Adult Acute Myeloid Leukemia
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
The study objective is to compare the efficacy and safety of US-ATG-F as a supplement to standard of care prophylaxis versus standard of care prophylaxis alone in moderate to severe chronic GVHD-free survival.
- Conditions
- GVHD, Adult Acute Myeloid Leukemia, Adult Acute Lymphoid Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01295710
- Testing
- US-ATG-F
- Where
- 28 sites in United States, Australia
- Volunteers
- 260 people
- Sponsor
- Neovii Biotech